Skip to main content

Advertisement

Table 2 BMFS comparison according to risk factors

From: Risk factors and treatments for brain metastasis in patients with adenocarcinoma of the lung: a retrospective analysis of 373 patients

  Univariate Multivariate
Variables BMFS(month) 95%CI P value P value RR 95%CI
Gender    0.25 0.072 0.293 0.077-1.114
 Male 37 31.2-42.7     
 Female 36 30.1-41.8     
Age    0.006 0.006 0.201 0.065-0.624
  ≤ 60 32 22.9-41.0     
  > 60 70 27.9-112.0     
Stage    < 0.001 0.68 1.166 0.554-2.455
 I/II 114 47.3-180.6     
 III/IV 27 20.7-33.2     
T status    0.009 0.43 1.648 0.469-5.791
 T1-2 46 19.0-72.9     
 T3-4 29 20.1-37.8     
N status    < 0.001 0.041 2.891 1.045-7.996
 N0-1 83 31.5-134.4     
 N2-3 25 15.5-34.4     
EGFR status    0.018 0.57 1.350 0.478-3.818
 Wild-type 35 0-70.6     
 Sensitive mutation 13 10.6-15.3     
Histology    0.02 0.38 0.402 0.051-3.155
 Adenocarcinoma 35 30.9-39.0     
 Non- Adenocarcinoma Not reached      
Smoking status    0.69 0.18 0.418 0.115-1.518
 Never 36 29.2-42.7     
 Current 37 31.3-42.7     
  1. Stage was not analyzed simultaneously with T/N status in multivariate analysis
  2. Abbreviations: BMFS brain-metastasis-free survival, EGFR epidermal growth factor receptor